<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562380</url>
  </required_header>
  <id_info>
    <org_study_id>AMGEN-479</org_study_id>
    <secondary_id>CDR0000577404</secondary_id>
    <secondary_id>AMGEN-20050118</secondary_id>
    <secondary_id>VU-VICC-050630</secondary_id>
    <secondary_id>VU-VICC-PHI-0542</secondary_id>
    <nct_id>NCT00562380</nct_id>
  </id_info>
  <brief_title>AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 479 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways.&#xD;
      Some block the ability of cancer cells to grow and spread. Others find cancer cells and help&#xD;
      kill them or carry cancer-killing substances to them.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of AMG-479 in treating&#xD;
      patients with advanced solid tumors or non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the safety and pharmacokinetics of anti-IGF-1R fully human monoclonal antibody&#xD;
           AMG-479 (AMG-479) after multiple intravenous administrations in adult patients with&#xD;
           histologically documented advanced solid tumors that are refractory to standard therapy&#xD;
           or for which no curative therapy is available.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the tolerability and to determine the maximum tolerated dose of AMG-479.&#xD;
&#xD;
        -  To assess tumor glucose metabolism using PET/CT scanning with the tracer fludeoxyglucose&#xD;
           F 18.&#xD;
&#xD;
        -  To measure insulin-like growth factor receptor (IGF-1R) levels on peripheral blood&#xD;
           cells.&#xD;
&#xD;
        -  To establish whether human anti-human antibodies to AMG-479 develop in patients with&#xD;
           advanced solid tumors.&#xD;
&#xD;
        -  To measure the tumor response by modified Response Evaluation Criteria in Solid Tumors.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  To investigate bone turnover markers.&#xD;
&#xD;
        -  To investigate potential biomarker development by biochemical analysis in blood cells&#xD;
           and tumor cells.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Part 1 (dose-escalation): Patients receive escalating doses of anti-IGF-1R fully human&#xD;
           monoclonal antibody AMG-479 (AMG-479) IV over 1 hour on days 1, 15, and 29. Patients are&#xD;
           evaluated in week 8, and those who demonstrate an objective tumor response or stable&#xD;
           disease continue treatment beginning on day 57. Treatment with AMG-479 repeats every 2&#xD;
           weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Part 2 (randomized dose-expansion): Patients are randomized to one of two dose regimens.&#xD;
&#xD;
             -  Arm I: Patients receive AMG-479 IV over 1 hour at a lower dose on day 1.&#xD;
&#xD;
             -  Arm II: Patients receive AMG-479 IV over 1 hour at a higher dose on day 1.&#xD;
                Treatment repeats every 14 days in the absence of disease progression or&#xD;
                unacceptable toxicity. Tumor tissue is obtained at baseline and after 4 weeks of&#xD;
                study therapy for biomarker analysis.&#xD;
&#xD;
      Blood is drawn periodically for biomarker analysis (insulin-like growth factor [IGF]-1,&#xD;
      IGF-binding protein 3 [IGF-BP3], IGF-1 receptor [IGF-1R], cross-linked c-telopeptides of type&#xD;
      1 collagen [CTx], bone-specific alkaline phosphatase [BSAP], and tartrate-resistant acid&#xD;
      phosphatase [TRAP5b]) and pharmacokinetic studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed for at least 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of insulin-like growth factor receptor-1 (IGF-1R) on peripheral blood cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response measured by modified RECIST</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor glucose metabolism as measured by fludeoxyglucose F 18-PET/CT scan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-AMG-479 antibody formation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of dose-limiting toxicities and the severity of adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of cross-linked c-telopeptides of type 1 collagen and bone-specific alkaline phosphatase (may also include tartrate-resistant acid phosphatase 5b) in blood</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating levels of IGF-1R and IGF-BP3</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Lymphoma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ganitumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumors or non-Hodgkin&#xD;
             lymphoma that is refractory to standard treatment or for which no curative therapy is&#xD;
             available&#xD;
&#xD;
          -  Tumor tissue that is accessible for biopsy by using minimally invasive procedures and&#xD;
             must consent to undergo biopsies of the tumor (part 2)&#xD;
&#xD;
               -  Exception for patients with Ewing family tumors or desmoplastic small round cell&#xD;
                  tumors whose anatomic location would pose an increase in the risk of injury due&#xD;
                  to biopsy (i.e., bleeding or pneumothorax)&#xD;
&#xD;
          -  Willing to provide existing and/or future paraffin-embedded tumor samples&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Primary CNS tumors or hematological malignancies, other than non-Hodgkin lymphoma&#xD;
&#xD;
          -  Primary hepatic tumors or at increased risk for hepatic tumors, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Hepatitis of any etiology&#xD;
&#xD;
               -  Alcohol abuse or dependency&#xD;
&#xD;
               -  Hepatic adenoma&#xD;
&#xD;
               -  Follicular nodular hyperplasia&#xD;
&#xD;
               -  Autoimmune conditions associated with biliary tract cancer&#xD;
&#xD;
               -  Alpha 1 antitrypsin deficiency&#xD;
&#xD;
               -  Hemochromatosis&#xD;
&#xD;
               -  History of vinyl chloride or thorotrast/thorium dioxide exposure&#xD;
&#xD;
          -  History of histiocytic (Kupffer cell) neoplasia&#xD;
&#xD;
          -  Presence of untreated or symptomatic CNS metastases or symptoms of brain metastases&#xD;
&#xD;
          -  Presence of ascites or pleural effusion requiring medical intervention&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to provide fasting blood samples for triglyceride and glucose laboratory tests&#xD;
&#xD;
          -  Able to fast for 4-6 hours for fludeoxyglucose F18-PET/CT scan&#xD;
&#xD;
          -  Controlled type 1 or 2 diabetes (defined as hemoglobin A1c &lt; 8.0% and fasting blood&#xD;
             glucose level &lt; 160 mg/dL) allowed for part 2 only&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of clinically significant hypoglycemia or hyperglycemia (in the opinion of the&#xD;
             investigator)&#xD;
&#xD;
          -  Myocardial infarction within the past year&#xD;
&#xD;
          -  Unstable or uncontrolled disease/condition related to or impacting cardiac function,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  NYHA class III or IV heart disease&#xD;
&#xD;
               -  Uncontrolled hypertension (diastolic BP &gt; 90 mm Hg and systolic BP &gt; 150 mm Hg)&#xD;
&#xD;
               -  Clinically significant cardiac arrhythmia&#xD;
&#xD;
               -  CTCAE version 3.0 ≥ grade 2&#xD;
&#xD;
               -  Clinically significant electrocardiogram abnormalities&#xD;
&#xD;
          -  History of arterial or venous (deep vein) thrombosis within the past year&#xD;
&#xD;
          -  History of bleeding diathesis&#xD;
&#xD;
          -  History of chronic hepatitis&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Unable to tolerate intravenous administration&#xD;
&#xD;
          -  Known sensitivity to mammalian-derived products&#xD;
&#xD;
          -  ANC &lt; 1,500/mm^3 (without filgrastim [G-CSF] support within the past 2 weeks)&#xD;
&#xD;
          -  Platelet count &lt; 100,000/mm^3 (without transfusion within the past 2 weeks)&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL (without transfusion within the past 4 weeks)&#xD;
&#xD;
          -  PT/PTT &gt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 x ULN&#xD;
&#xD;
          -  AST and ALT &gt; 2.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  Urinary protein excretion &gt; 1,000 mg/day (≥ 2+ using dipstick analysis)&#xD;
&#xD;
          -  Any kind of disorder that compromises the ability of the patient to give written&#xD;
             informed consent and/or comply with study procedures&#xD;
&#xD;
          -  Any comorbid medical condition, that in the sponsor's or investigator's opinion, may&#xD;
             put the patients at significant risk&#xD;
&#xD;
          -  Known sensitivity to any of the products to be administered during dosing&#xD;
&#xD;
          -  Unresolved toxicities &gt; grade 1 from prior anticancer therapy, excluding alopecia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior antitumor treatment within the past 28 days&#xD;
&#xD;
               -  Palliative external-beam radiotherapy to a lesion not used for RECIST measurement&#xD;
                  is acceptable during study for symptom management if patient is stable or&#xD;
                  improving and not progressing&#xD;
&#xD;
          -  At least 30 days since prior and no concurrent enrollment in another clinical trial&#xD;
             involving medication&#xD;
&#xD;
          -  No antibody therapy for the treatment of underlying malignancy within the past 8 weeks&#xD;
&#xD;
          -  No concurrent or prior anticoagulation therapy, except low-dose warfarin (&lt; 2 mg/day)&#xD;
             for prophylaxis against central venous catheter thrombosis&#xD;
&#xD;
          -  No concurrent insulin (except diabetic patients enrolled in dose expansion [part 2] of&#xD;
             the study)&#xD;
&#xD;
          -  No other concurrent investigational procedures&#xD;
&#xD;
          -  No concurrent blood or blood-product transfusions&#xD;
&#xD;
          -  No concurrent herbal medications&#xD;
&#xD;
          -  No other concurrent anticancer therapy including chemotherapy or hormonal therapy&#xD;
&#xD;
               -  Gonadotropic releasing-hormone agonists or antagonists allowed for advanced&#xD;
                  prostate cancer&#xD;
&#xD;
          -  No major surgery within the past month and none planned for 28 days after completion&#xD;
             of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mace L. Rothenberg, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>adult desmoplastic small round cell tumor</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

